Federated Hermes Inc. lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 9.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,890 shares of the biotechnology company’s stock after selling 733 shares during the quarter. Federated Hermes Inc.’s holdings in United Therapeutics were worth $2,195,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the business. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics in the second quarter worth approximately $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the second quarter worth approximately $33,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $32,000. Finally, Benjamin F. Edwards & Company Inc. boosted its position in shares of United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.
Insider Transactions at United Therapeutics
In related news, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now directly owns 5,107 shares in the company, valued at approximately $1,626,988.06. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The disclosure for this sale can be found here. Insiders sold 110,922 shares of company stock worth $36,541,398 over the last quarter. Corporate insiders own 12.50% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Report on United Therapeutics
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $353.00 on Friday. The company has a market capitalization of $15.70 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The business has a fifty day simple moving average of $338.55 and a two-hundred day simple moving average of $290.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same period last year, the business posted $5.24 EPS. The company’s revenue was up 19.8% compared to the same quarter last year. On average, analysts expect that United Therapeutics Co. will post 24.86 earnings per share for the current year.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Dividend Payout Ratio Calculator
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Dividend Capture Strategy: What You Need to Know
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.